FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131589968> ?p ?o ?g. }

• W2131589968 endingPage "3060" @default.
• W2131589968 startingPage "3053" @default.
• W2131589968 abstract "To assess the efficacy of neoadjuvant paclitaxel and carboplatin (TC) followed by concurrent cisplatin and radiotherapy (RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to monitor treatment response with plasma Epstein-Barr virus (EBV) DNA.Thirty-one patients with International Union Against Cancer stages III and IV undifferentiated NPC had two cycles of paclitaxel (70 mg/m2 on days 1, 8, and 15) and carboplatin (area under the curve 6 mg/mL/min on day 1) on a 3-weekly cycle, followed by 6 to 8 weeks of cisplatin (40 mg/m2 weekly) and RT at 66 Gy in 2-Gy fractions. Plasma EBV DNA was measured serially using the real-time quantitative polymerase chain reaction method. Results All patients completed planned treatment. Response to neoadjuvant TC was as follows: 12 patients (39%) achieved partial response (PR) and 18 achieved (58%) complete response (CR) in regional nodes; five patients (16%) achieved PR and no patients achieved CR in nasopharynx. At 6 weeks after RT, one patient (3%) achieved PR and 30 patients (97%) achieved CR in regional nodes, and 31 patients (100%) achieved CR in nasopharynx; 29 patients (93%) had EBV DNA level of less than 500 copies/mL. Neoadjuvant TC was well tolerated, and the most common acute toxicity of cisplatin plus RT was grade 3 mucositis (55%). At median follow-up of 33.7 months (range, 7 to 39.3 months), six distant and three locoregional failures occurred. Plasma EBV DNA level increased significantly in eight of nine patients who experienced treatment failure but did not increase in those who did not. The 2-year overall and progression-free survival rates were 91.8% and 78.5%, respectively. CONCLUSION This strategy was feasible and resulted in excellent local tumor control. Serial plasma EBV DNA provides a noninvasive method of monitoring response in NPC." @default.
• W2131589968 created "2016-06-24" @default.
• W2131589968 creator A5005665172 @default.
• W2131589968 creator A5006449106 @default.
• W2131589968 creator A5007089296 @default.
• W2131589968 creator A5023271276 @default.
• W2131589968 creator A5023364103 @default.
• W2131589968 creator A5025112401 @default.
• W2131589968 creator A5033886818 @default.
• W2131589968 creator A5037091443 @default.
• W2131589968 creator A5040744782 @default.
• W2131589968 creator A5042632184 @default.
• W2131589968 creator A5049296676 @default.
• W2131589968 creator A5052600455 @default.
• W2131589968 creator A5054589139 @default.
• W2131589968 creator A5062767641 @default.
• W2131589968 creator A5064464273 @default.
• W2131589968 creator A5065283428 @default.
• W2131589968 creator A5066717752 @default.
• W2131589968 creator A5072880961 @default.
• W2131589968 creator A5087988793 @default.
• W2131589968 creator A5090863040 @default.
• W2131589968 date "2004-08-01" @default.
• W2131589968 modified "2023-10-01" @default.
• W2131589968 title "Phase II Study of Neoadjuvant Carboplatin and Paclitaxel Followed by Radiotherapy and Concurrent Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: Therapeutic Monitoring With Plasma Epstein-Barr Virus DNA" @default.
• W2131589968 cites W1652755023 @default.
• W2131589968 cites W182988086 @default.
• W2131589968 cites W1902822116 @default.
• W2131589968 cites W1976661936 @default.
• W2131589968 cites W1984396523 @default.
• W2131589968 cites W1984452164 @default.
• W2131589968 cites W1988053404 @default.
• W2131589968 cites W2014401523 @default.
• W2131589968 cites W2024599177 @default.
• W2131589968 cites W2029409133 @default.
• W2131589968 cites W2045943543 @default.
• W2131589968 cites W2051367322 @default.
• W2131589968 cites W2075214861 @default.
• W2131589968 cites W2075736071 @default.
• W2131589968 cites W2084803897 @default.
• W2131589968 cites W2093703907 @default.
• W2131589968 cites W2111140446 @default.
• W2131589968 cites W2125919881 @default.
• W2131589968 cites W2127706390 @default.
• W2131589968 cites W2128967557 @default.
• W2131589968 cites W2135227912 @default.
• W2131589968 cites W2149067175 @default.
• W2131589968 cites W2151645021 @default.
• W2131589968 cites W2168593891 @default.
• W2131589968 cites W2314660029 @default.
• W2131589968 cites W2342207742 @default.
• W2131589968 doi "https://doi.org/10.1200/jco.2004.05.178" @default.
• W2131589968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15284255" @default.
• W2131589968 hasPublicationYear "2004" @default.
• W2131589968 type Work @default.
• W2131589968 sameAs 2131589968 @default.
• W2131589968 citedByCount "114" @default.
• W2131589968 countsByYear W21315899682012 @default.
• W2131589968 countsByYear W21315899682013 @default.
• W2131589968 countsByYear W21315899682014 @default.
• W2131589968 countsByYear W21315899682015 @default.
• W2131589968 countsByYear W21315899682016 @default.
• W2131589968 countsByYear W21315899682017 @default.
• W2131589968 countsByYear W21315899682018 @default.
• W2131589968 countsByYear W21315899682020 @default.
• W2131589968 countsByYear W21315899682021 @default.
• W2131589968 countsByYear W21315899682022 @default.
• W2131589968 countsByYear W21315899682023 @default.
• W2131589968 crossrefType "journal-article" @default.
• W2131589968 hasAuthorship W2131589968A5005665172 @default.
• W2131589968 hasAuthorship W2131589968A5006449106 @default.
• W2131589968 hasAuthorship W2131589968A5007089296 @default.
• W2131589968 hasAuthorship W2131589968A5023271276 @default.
• W2131589968 hasAuthorship W2131589968A5023364103 @default.
• W2131589968 hasAuthorship W2131589968A5025112401 @default.
• W2131589968 hasAuthorship W2131589968A5033886818 @default.
• W2131589968 hasAuthorship W2131589968A5037091443 @default.
• W2131589968 hasAuthorship W2131589968A5040744782 @default.
• W2131589968 hasAuthorship W2131589968A5042632184 @default.
• W2131589968 hasAuthorship W2131589968A5049296676 @default.
• W2131589968 hasAuthorship W2131589968A5052600455 @default.
• W2131589968 hasAuthorship W2131589968A5054589139 @default.
• W2131589968 hasAuthorship W2131589968A5062767641 @default.
• W2131589968 hasAuthorship W2131589968A5064464273 @default.
• W2131589968 hasAuthorship W2131589968A5065283428 @default.
• W2131589968 hasAuthorship W2131589968A5066717752 @default.
• W2131589968 hasAuthorship W2131589968A5072880961 @default.
• W2131589968 hasAuthorship W2131589968A5087988793 @default.
• W2131589968 hasAuthorship W2131589968A5090863040 @default.
• W2131589968 hasBestOaLocation W21315899681 @default.
• W2131589968 hasConcept C126322002 @default.
• W2131589968 hasConcept C143998085 @default.
• W2131589968 hasConcept C2776694085 @default.
• W2131589968 hasConcept C2777292972 @default.
• W2131589968 hasConcept C2777546739 @default.
• W2131589968 hasConcept C2778239845 @default.
• W2131589968 hasConcept C2778496288 @default.
• W2131589968 hasConcept C2778997737 @default.

• next